Cargando…

Evaluation of the Safety and Immunogenicity of Fractional Intradermal COVID-19 Vaccines as a Booster: A Pilot Study

Intradermal vaccination using fractional dosages of the standard vaccine dose is one strategy to improve access to COVID-19 immunization. We conducted a pilot study in healthy adults in Thailand to evaluate the safety and immunogenicity of intradermal administration of fractional doses of ChAdOx1 (1...

Descripción completa

Detalles Bibliográficos
Autores principales: Niyomnaitham, Suvimol, Chatsiricharoenkul, Somruedee, Toh, Zheng Quan, Senawong, Sansnee, Pheerapanyawaranun, Chatkamol, Phumiamorn, Supaporn, Licciardi, Paul V., Chokephaibulkit, Kulkanya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505744/
https://www.ncbi.nlm.nih.gov/pubmed/36146575
http://dx.doi.org/10.3390/vaccines10091497
_version_ 1784796549452136448
author Niyomnaitham, Suvimol
Chatsiricharoenkul, Somruedee
Toh, Zheng Quan
Senawong, Sansnee
Pheerapanyawaranun, Chatkamol
Phumiamorn, Supaporn
Licciardi, Paul V.
Chokephaibulkit, Kulkanya
author_facet Niyomnaitham, Suvimol
Chatsiricharoenkul, Somruedee
Toh, Zheng Quan
Senawong, Sansnee
Pheerapanyawaranun, Chatkamol
Phumiamorn, Supaporn
Licciardi, Paul V.
Chokephaibulkit, Kulkanya
author_sort Niyomnaitham, Suvimol
collection PubMed
description Intradermal vaccination using fractional dosages of the standard vaccine dose is one strategy to improve access to COVID-19 immunization. We conducted a pilot study in healthy adults in Thailand to evaluate the safety and immunogenicity of intradermal administration of fractional doses of ChAdOx1 (1/5th of standard dosage) or BNT162b2 (1/6th of standard dosage) to individuals previously vaccinated (prime) with two-dose intramuscular CoronaVac, ChAdOx1 or BNT162b2. Following an initial immunogenicity exploratory phase for each vaccine combination group (n = 10), a total of 135 participants (n = 45 per group) were recruited to 3 groups (CoronaVac prime-intradermal BNT162b2 boost, CoronaVac prime-intradermal ChAdOx1 boost and ChAdOx1 prime-intradermal BNT162b2 boost) and their immunogenicity data were compared to a previous cohort who received the same vaccine intramuscularly. Two weeks following booster vaccination, neutralizing antibodies against the delta variant were similar between the participants who received intradermal and intramuscular vaccination. However, neutralizing antibodies against the omicron variant in the intradermal BNT162b2 boost groups were ~6-fold lower, while the levels in the ChAdOx1 boost group were similar compared to their respective vaccine regimen given intramuscularly. The intradermal booster significantly increased spike-specific T cell responses in all three groups from pre-booster levels. Local and systemic adverse reactions were milder in intradermal compared to intramuscular injections. Further studies are needed to evaluate the clinical relevance of these findings and the feasibility of administration of intradermal COVID-19 vaccines.
format Online
Article
Text
id pubmed-9505744
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95057442022-09-24 Evaluation of the Safety and Immunogenicity of Fractional Intradermal COVID-19 Vaccines as a Booster: A Pilot Study Niyomnaitham, Suvimol Chatsiricharoenkul, Somruedee Toh, Zheng Quan Senawong, Sansnee Pheerapanyawaranun, Chatkamol Phumiamorn, Supaporn Licciardi, Paul V. Chokephaibulkit, Kulkanya Vaccines (Basel) Article Intradermal vaccination using fractional dosages of the standard vaccine dose is one strategy to improve access to COVID-19 immunization. We conducted a pilot study in healthy adults in Thailand to evaluate the safety and immunogenicity of intradermal administration of fractional doses of ChAdOx1 (1/5th of standard dosage) or BNT162b2 (1/6th of standard dosage) to individuals previously vaccinated (prime) with two-dose intramuscular CoronaVac, ChAdOx1 or BNT162b2. Following an initial immunogenicity exploratory phase for each vaccine combination group (n = 10), a total of 135 participants (n = 45 per group) were recruited to 3 groups (CoronaVac prime-intradermal BNT162b2 boost, CoronaVac prime-intradermal ChAdOx1 boost and ChAdOx1 prime-intradermal BNT162b2 boost) and their immunogenicity data were compared to a previous cohort who received the same vaccine intramuscularly. Two weeks following booster vaccination, neutralizing antibodies against the delta variant were similar between the participants who received intradermal and intramuscular vaccination. However, neutralizing antibodies against the omicron variant in the intradermal BNT162b2 boost groups were ~6-fold lower, while the levels in the ChAdOx1 boost group were similar compared to their respective vaccine regimen given intramuscularly. The intradermal booster significantly increased spike-specific T cell responses in all three groups from pre-booster levels. Local and systemic adverse reactions were milder in intradermal compared to intramuscular injections. Further studies are needed to evaluate the clinical relevance of these findings and the feasibility of administration of intradermal COVID-19 vaccines. MDPI 2022-09-08 /pmc/articles/PMC9505744/ /pubmed/36146575 http://dx.doi.org/10.3390/vaccines10091497 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Niyomnaitham, Suvimol
Chatsiricharoenkul, Somruedee
Toh, Zheng Quan
Senawong, Sansnee
Pheerapanyawaranun, Chatkamol
Phumiamorn, Supaporn
Licciardi, Paul V.
Chokephaibulkit, Kulkanya
Evaluation of the Safety and Immunogenicity of Fractional Intradermal COVID-19 Vaccines as a Booster: A Pilot Study
title Evaluation of the Safety and Immunogenicity of Fractional Intradermal COVID-19 Vaccines as a Booster: A Pilot Study
title_full Evaluation of the Safety and Immunogenicity of Fractional Intradermal COVID-19 Vaccines as a Booster: A Pilot Study
title_fullStr Evaluation of the Safety and Immunogenicity of Fractional Intradermal COVID-19 Vaccines as a Booster: A Pilot Study
title_full_unstemmed Evaluation of the Safety and Immunogenicity of Fractional Intradermal COVID-19 Vaccines as a Booster: A Pilot Study
title_short Evaluation of the Safety and Immunogenicity of Fractional Intradermal COVID-19 Vaccines as a Booster: A Pilot Study
title_sort evaluation of the safety and immunogenicity of fractional intradermal covid-19 vaccines as a booster: a pilot study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505744/
https://www.ncbi.nlm.nih.gov/pubmed/36146575
http://dx.doi.org/10.3390/vaccines10091497
work_keys_str_mv AT niyomnaithamsuvimol evaluationofthesafetyandimmunogenicityoffractionalintradermalcovid19vaccinesasaboosterapilotstudy
AT chatsiricharoenkulsomruedee evaluationofthesafetyandimmunogenicityoffractionalintradermalcovid19vaccinesasaboosterapilotstudy
AT tohzhengquan evaluationofthesafetyandimmunogenicityoffractionalintradermalcovid19vaccinesasaboosterapilotstudy
AT senawongsansnee evaluationofthesafetyandimmunogenicityoffractionalintradermalcovid19vaccinesasaboosterapilotstudy
AT pheerapanyawaranunchatkamol evaluationofthesafetyandimmunogenicityoffractionalintradermalcovid19vaccinesasaboosterapilotstudy
AT phumiamornsupaporn evaluationofthesafetyandimmunogenicityoffractionalintradermalcovid19vaccinesasaboosterapilotstudy
AT licciardipaulv evaluationofthesafetyandimmunogenicityoffractionalintradermalcovid19vaccinesasaboosterapilotstudy
AT chokephaibulkitkulkanya evaluationofthesafetyandimmunogenicityoffractionalintradermalcovid19vaccinesasaboosterapilotstudy